10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
ABBOTT LABORATORIES | ||
Ticker: ABT Fiscal Year: 2019 | ||
Consolidated Balance Sheet | ||
Period Ending Dec 31, 2019 10-K (Filed: Feb 21, 2020) | ||
| (In Millions, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2019 | Dec 31, 2018 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $ 3,860 | 3,844 |
| Investments, primarily bank time deposits and U.S. treasury bills | 280 | 242 |
| Trade receivables, less allowances of - 2019: $384; 2018: $314 | 5,425 | 5,182 |
| Inventories: | ||
| Finished products | 2,784 | 2,407 |
| Work in process | 560 | 499 |
| Materials | 972 | 890 |
| Total inventories | 4,316 | 3,796 |
| Other prepaid expenses and receivables | 1,786 | 1,568 |
| Total current assets | 15,667 | 14,632 |
| Investments | 883 | 897 |
| Property and equipment, at cost: | ||
| Land | 519 | 501 |
| Buildings | 3,702 | 3,555 |
| Equipment | 11,468 | 10,756 |
| Construction in progress | 1,110 | 894 |
| Property and equipment, at cost | 16,799 | 15,706 |
| Less: accumulated depreciation and amortization | 8,761 | 8,143 |
| Net property and equipment | 8,038 | 7,563 |
| Intangible assets, net of amortization | 17,025 | 18,942 |
| Goodwill | 23,195 | 23,254 |
| Deferred income taxes and other assets | 3,079 | 1,885 |
| Total Assets | 67,887 | 67,173 |
| Liabilities and Shareholders' Investment | ||
| Current liabilities: | ||
| Short-term borrowings | 201 | 200 |
| Trade accounts payable | 3,252 | 2,975 |
| Salaries, wages and commissions | 1,237 | 1,182 |
| Other accrued liabilities | 4,035 | 3,780 |
| Dividends payable | 635 | 563 |
| Income taxes payable | 226 | 305 |
| Current portion of long-term debt | 1,277 | 7 |
| Total current liabilities | 10,863 | 9,012 |
| Long-term debt | 16,661 | 19,359 |
| Post-employment obligations and other long-term liabilities | 9,062 | 8,080 |
| Commitments and contingencies | ||
| Shareholders' investment: | ||
| Preferred shares, one dollar par value Authorized - 1,000,000 shares, none issued | ||
| Common shares, without par value Authorized - 2,400,000,000 shares, Issued at stated capital amount - Shares: 2019: 1,976,855,085; 2018: 1,971,189,465 | 23,853 | 23,512 |
| Common shares held in treasury, at cost - Shares: 2019: 214,351,838; 2018: 215,570,043 | (10,147) | (9,962) |
| Earnings employed in the business | 25,847 | 24,560 |
| Accumulated other comprehensive income (loss) | (8,465) | (7,586) |
| Total Abbott Shareholders' Investment | 31,088 | 30,524 |
| Noncontrolling interests in subsidiaries | 213 | 198 |
| Total Shareholders' Investment | 31,301 | 30,722 |
| Total Liabilities and Shareholders' Investment | 67,887 | 67,173 |
| External Links | |
| ABBOTT LABORATORIES (ABT) Fiscal Year 2019 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |